VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Key features of the PANGEA model: improving risk stratification in myeloma

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses key features of the PANGEA model, which aims to more precisely risk stratify patients with smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS), and further highlights how this model may impact clinical practice. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter